Surgical Therapy and Survival in Young Patients With Stage I-II Hepatocellular Carcinoma: A Retrospective Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 664
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.
详细描述
The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients were diagnosed with colorectal cancer only;
- •Patients with simultaneous metastasis of liver and lung cancer cells;
- •Patients without metastasis resection;
- •whether they underwent palliative primary tumor resection was known;
- •Their cause of death was known;
- •Their survival time were known and greater than 0 month;
- •Patients were diagnosed with microscopic confirmation.
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: 2004.1.1-2013.12.31
Overall survival was defined as the duration between the surgery and death or the last follow-up
次要结局
- Cancer-specific survival(2004.1.1-2013.12.31)
研究者
Linzhu Zhai
Director
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine